Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is phosphaturic mesenchymal tumor?
Phosphaturic mesenchymal tumor (PMT) is a rare, usually small and slow-growing tumor of the soft tissue or bone. What makes it remarkable is not its size but a hormone it overproduces called FGF23. Excess FGF23 makes the kidneys waste phosphate into the urine, leading to low blood phosphate and a condition called tumor-induced osteomalacia — a softening of the bones that causes deep bone pain, muscle weakness, fatigue, and fractures, often for years before the tiny tumor is found. Because the tumor is frequently small and hidden (in a bone, foot, or deep tissue), specialized imaging such as a DOTATATE or octreotide scan is often needed to locate it. The good news is that PMT is almost always benign, and completely removing it cures the disease: FGF23 levels fall, blood phosphate normalizes, and the bone disease reverses, often dramatically. When a tumor cannot be found or safely removed, medicines and other local treatments can control the condition.
The main types
Doctors group phosphaturic mesenchymal tumor by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Benign phosphaturic mesenchymal tumor | The vast majority. A small, hormone-secreting tumor that is cured once it is completely removed. |
| Soft-tissue vs. bone location | PMTs can arise in soft tissue (such as the foot, thigh, or groin) or within a bone; the location affects how the tumor is found and removed. |
| Malignant phosphaturic mesenchymal tumor (rare) | A small minority show malignant features and can recur or spread; these need more aggressive treatment and long-term follow-up. |
Staging, in plain terms
PMT is not staged like a typical cancer because it is almost always benign. The practical issues are whether the tumor can be located, whether it can be completely removed, and whether the bone-softening disease (osteomalacia) is controlled. Rare malignant cases are managed like a soft-tissue sarcoma.
| No formal cancer staging | What it generally means |
|---|---|
| Localized, removable | The typical situation: a single small tumor that, once located, is cured by complete removal, with the bone disease reversing afterward. |
| Localized, hard to find or remove | The tumor is in a difficult spot or cannot be found; managed with medicines (phosphate/vitamin D, burosumab) and local treatments until removal is possible. |
| Malignant / recurrent (rare) | Uncommon aggressive tumors that recur or spread; treated more intensively at an expert center and followed long-term. |
The standard of care
Phosphaturic Mesenchymal Tumor is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Locating the tumor
Because PMTs are often tiny and hidden, specialized functional imaging (DOTATATE PET or octreotide scan) plus MRI/CT is used to pinpoint the tumor before surgery.
Complete surgical removal (curative)
Removing the entire tumor with a margin of normal tissue cures most patients: FGF23 drops within hours, blood phosphate normalizes within days, and the bone disease heals over the following months.
Burosumab (FGF23-blocking medicine)
When the tumor cannot be found or safely removed, burosumab — an antibody that blocks FGF23 — corrects the low phosphate, relieves symptoms, and improves quality of life; phosphate and active vitamin D supplements are an alternative or supportive measure.
Long-term monitoring
Blood phosphate and FGF23 are tracked after treatment to confirm cure and to detect the rare recurrence early.
How radiation treatment works
Radiation damages the DNA inside tumor cells so they can no longer divide and function, while normal cells repair themselves more effectively. In phosphaturic mesenchymal tumor, surgery is the cure of choice; radiation is reserved for tumors that cannot be safely removed, where targeting the tumor can reduce its size and its overproduction of FGF23, helping the low-phosphate bone disease improve. Modern focused techniques concentrate the dose on the small tumor and spare nearby structures, and radiation is delivered as short, painless sessions that leave no radioactivity in your body.
The main ways radiation is delivered for phosphaturic mesenchymal tumor:
Radiation for unresectable tumors
When a tumor cannot be surgically removed — for example, when it sits in a difficult or critical location — targeted radiation can shrink it or reduce its hormone output, helping control the bone disease.
Stereotactic / focused radiation
Precise high-dose radiation can treat a small, well-defined tumor in a hard-to-reach spot, or an isolated recurrence, while sparing surrounding tissue.
Image-guided ablation (alternative local therapy)
Some small tumors can be destroyed with image-guided techniques such as radiofrequency or cryoablation when surgery is not ideal — chosen by the care team based on the tumor's location.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Burosumab for tumor-induced osteomalacia: Trials and real-world series show that burosumab, an antibody that blocks excess FGF23, corrects low blood phosphate, heals fractures, and improves pain and fatigue in patients whose tumor cannot be removed.[1]
Burosumab tumor-induced osteomalacia studies (2021–2026)
Functional imaging finds hidden tumors: DOTATATE PET and related somatostatin-receptor scans have greatly improved the ability to locate these often tiny, hidden tumors, allowing curative surgery in patients who were undiagnosed for years.[2]
Nuclear medicine and endocrine tumor localization reviews (2020–2025)
Surgery reverses the bone disease: Case series confirm that complete removal of the tumor rapidly normalizes phosphate and FGF23 and reverses osteomalacia, underscoring that finding and removing the tumor is the definitive cure.[3]
Endocrine and orthopedic outcome series (2022–2025)
Common questions
Why did this small tumor make my bones hurt and weaken? The tumor overproduces a hormone called FGF23, which makes your kidneys lose phosphate into the urine. Low phosphate softens the bones (osteomalacia), causing deep bone pain, muscle weakness, and fractures. Removing the tumor reverses this.
Why was my tumor so hard to find? Phosphaturic mesenchymal tumors are often very small and can hide in a bone, foot, or deep tissue. Specialized scans such as a DOTATATE PET are used to locate them, after which surgery can cure the disease.
What if my tumor can't be removed? If the tumor can't be found or safely removed, medicines can control the condition — most notably burosumab, which blocks the FGF23 hormone, along with phosphate and active vitamin D. Targeted radiation or ablation may also be used to treat the tumor itself.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Burosumab tumor-induced osteomalacia studies (2021–2026) (no indexed identifier — see your care team) ↩
- Nuclear medicine and endocrine tumor localization reviews (2020–2025) (no indexed identifier — see your care team) ↩
- Endocrine and orthopedic outcome series (2022–2025) (no indexed identifier — see your care team) ↩